Literature DB >> 31965356

Fluconazole Prophylaxis in Prevention of Symptomatic Candida Vaginitis.

Kannika Story1, Ryan Sobel2.   

Abstract

Due to broad spectrum susceptibility of Candida species to fluconazole, its convenience as an oral agent, and predictable patient tolerance and safety, current practice guidelines recommend the use of long-term suppression regimens of fluconazole as prophylaxis for recurrent vulvovaginal candidiasis (RVVC), as well as in abbreviated doses when known trigger factors emerge and inevitable symptomatic episodes are predictable. However, recent concerns of fluconazole-resistant Candida albicans strains may impact fluconazole use, particularly, concerns of overuse. This literature review discusses current recommendations for prophylaxis of vulvovaginal candidiasis with fluconazole.

Entities:  

Keywords:  Boric acid; Candida; Candida albicans; Candida krusei; Candida parapsilosis; Fluconazole; Fluconazole prophylaxis; Fluconazole suppression therapy; Fluconazole-resistance; Nystatin; Recurrent vulvovaginal candidiasis; Resistant candida; Resistant vulvovaginal candidiasis; Vaginitis; Vulvovaginal candidiasis; Yeast infection

Year:  2020        PMID: 31965356     DOI: 10.1007/s11908-020-0712-7

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  12 in total

1.  Antifungal Susceptibility Profile of Candida Albicans Isolated from Vulvovaginal Candidiasis in Xinjiang Province of China.

Authors:  Liang Yan; Xiao-Dong Wang; Seyedmojtaba Seyedmousavi; Juan-Na Yuan; Palida Abulize; Wei-Hua Pan; Nong Yu; Ya-Li Yang; Hai-Qing Hu; Wan-Qing Liao; Shu-Wen Deng
Journal:  Mycopathologia       Date:  2019-04-09       Impact factor: 2.574

2.  Epidemiology and antifungal susceptibility patterns of Candida isolates from Greek women with vulvovaginal candidiasis.

Authors:  Sofia Maraki; Viktoria Eirini Mavromanolaki; Dimitra Stafylaki; Eleni Nioti; George Hamilos; Anna Kasimati
Journal:  Mycoses       Date:  2019-06-12       Impact factor: 4.377

3.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

4.  Fluconazole-resistant Candida albicans vulvovaginitis.

Authors:  Dror Marchaim; Leslie Lemanek; Suchitha Bheemreddy; Keith S Kaye; Jack D Sobel
Journal:  Obstet Gynecol       Date:  2012-12       Impact factor: 7.661

5.  Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies.

Authors:  Anick Bérard; Odile Sheehy; Jin-Ping Zhao; Jessica Gorgui; Sasha Bernatsky; Cristiano Soares de Moura; Michal Abrahamowicz
Journal:  CMAJ       Date:  2019-02-19       Impact factor: 8.262

Review 6.  Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations.

Authors:  J D Sobel; S Faro; R W Force; B Foxman; W J Ledger; P R Nyirjesy; B D Reed; P R Summers
Journal:  Am J Obstet Gynecol       Date:  1998-02       Impact factor: 8.661

7.  Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine.

Authors:  Jack D Sobel; Walter Chaim; Viji Nagappan; Deborah Leaman
Journal:  Am J Obstet Gynecol       Date:  2003-11       Impact factor: 8.661

8.  Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial).

Authors:  Gilbert Donders; Gert Bellen; Geert Byttebier; Luc Verguts; Piet Hinoul; Ronald Walckiers; Michel Stalpaert; Annie Vereecken; Johan Van Eldere
Journal:  Am J Obstet Gynecol       Date:  2008-10-30       Impact factor: 8.661

9.  Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes.

Authors:  Junko Yano; Jack D Sobel; Paul Nyirjesy; Ryan Sobel; Valerie L Williams; Qingzhao Yu; Mairi C Noverr; Paul L Fidel
Journal:  BMC Womens Health       Date:  2019-03-29       Impact factor: 2.809

10.  Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern.

Authors:  Adane Bitew; Yeshiwork Abebaw
Journal:  BMC Womens Health       Date:  2018-06-15       Impact factor: 2.809

View more
  4 in total

1.  New Peptide Based Fluconazole Conjugates with Expanded Molecular Targets.

Authors:  Wioletta Brankiewicz; Joanna Okońska; Katarzyna Serbakowska; Jan Lica; Marek Drab; Natalia Ptaszyńska; Anna Łęgowska; Krzysztof Rolka; Piotr Szweda
Journal:  Pharmaceutics       Date:  2022-03-23       Impact factor: 6.525

2.  Current and promising pharmacotherapeutic options for candidiasis.

Authors:  Liliana Scorzoni; Beth Burgwyn Fuchs; Juliana Campos Junqueira; Eleftherios Mylonakis
Journal:  Expert Opin Pharmacother       Date:  2021-02-04       Impact factor: 3.889

3.  Lived experience of medical management in recurrent vulvovaginal candidiasis: a qualitative study of an uncertain journey.

Authors:  Moira Bradfield Strydom; Ramesh L Walpola; Sara McMillan; Sohil Khan; Robert S Ware; Evelin Tiralongo
Journal:  BMC Womens Health       Date:  2022-09-19       Impact factor: 2.742

4.  New Approach to Antifungal Activity of Fluconazole Incorporated into the Porous 6-Anhydro-α-l-Galacto-β-d-Galactan Structures Modified with Nanohydroxyapatite for Chronic-Wound Treatments-In Vitro Evaluation.

Authors:  Justyna Rewak-Soroczynska; Paulina Sobierajska; Sara Targonska; Agata Piecuch; Lukasz Grosman; Jaroslaw Rachuna; Slawomir Wasik; Michal Arabski; Rafal Ogorek; Rafal J Wiglusz
Journal:  Int J Mol Sci       Date:  2021-03-18       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.